External open innovation partner programNovel therapeutic targets and drugs for the treatment of Proteinopathies
According to WHO, hundreds of millions of people worldwide are affected by neurological disorders. With the extension of life expectancy and the ageing of the general populations in both developed and developing countries, the prevalence of these diseases are likely to increase.
We are looking for proposals to identify new diseases-modifying targets and drugs for the treatment of proteinopathies with a focus on:
- Alzheimer’s disease: Tau and amyloid-beta proteins
- Parkinson’s disease: Alpha-Synuclein protein
At the preclinical stage, selected molecular targets and targets validation must be supported by clear scientific data deriving from in vitro, ex vivo, or animal models. Molecular targets identified in clinical trials are excluded.
All proposals will be assessed by our Research & Development team. Based on the level of interest within our research portfolio and the strategic fit of the proposals into Servier long-term research focus, we will enter into discussion with selected candidate(s), potentially leading to funding and partnership agreements.
Proponents that submit proposals of interest will be contacted within 6 to 8 weeks of submission to clarify additional details concerning the underlying science as well as intellectual property rights, timelines, etc.
Submit your proposal online (it takes about 15 minutes) in a form and length that is sufficient to provide the substance of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project and how that knowledge could be supplemented (i.e., what is additionally required to complete the project). Additional information, including references or other materials should be attached to facilitate the evaluation process.
While Servier will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
Servier is a leading pharmaceutical company headquartered in France. Committed to improving health worldwide, corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiology, metabolism, neuropsychiatry, oncology and rheumatology
Privately own company, Servier reinvests 25% of its turnover (€3.9 billion in 2015) in Research and development and all its profits in its growth
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 10 main types of partnering programs with Academia.